Bad blood : secrets and lies in a Silicon Valley startup / John Carreyrou.  (Text) (Text)

Carreyrou, John
Call no.: HD9995.H423U5 C377 2019aPublication: London : Picador, 2019Description: x, 339 pNotes: Reprint. Originally published: 2018.ISBN: 9781509868087 (pbk.); 1509868089 (pbk.)Subject(s): Holmes, Elizabeth, 1984-Theranos (Firm) -- HistoryHematologic equipment industry -- United StatesNew business enterprises -- Corrupt practices -- United States -- CasesSecurities fraud -- United States -- CasesLOC classification: HD9995.H423U5 | C377 2019a
Contents:A purposeful life -- The gluebot -- Apple envy -- Goodbye East Paly -- The childhood neighbor -- Sunny -- Dr. J -- The miniLab -- The wellness play -- "Who is LTC Shoemaker?" -- Lighting a Fuisz -- Ian Gibbons -- Chiat\Day -- Going live -- Unicorn -- The grandson -- Fame -- The Hippocratic Oath -- The tip -- The ambush -- Trade secrets -- La Mattanza -- Damage control -- The empress has no clothes -- Epilogue -- Afterword.
Summary: The full inside story of the breathtaking rise and shocking collapse of Theranos--the Enron of Silicon Valley--by the prize-winning journalist who first broke the story and pursued it to the end in the face of pressure and threats from the CEO and her lawyers. In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in an early fundraising round that valued the company at $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: the technology didn't work. For years, Holmes had been misleading investors, FDA officials, and her own employees. When Carreyrou, working at the Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both Carreyrou and the Journal were threatened with lawsuits. Undaunted, the newspaper ran the first of dozens of Theranos articles in late 2015. By early 2017, the company's value was zero and Holmes faced potential legal action from the government and her investors. Here is the riveting story of the biggest corporate fraud since Enron, a disturbing cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley.
แสดงรายการนี้ใน: TUBA-New Book-202002-01 (ENG) | You learn We Care :TUBA Book Recommendations (ENG)
แท็ก: ไม่มีแท็กจากห้องสมุดสำหรับชื่อเรื่องนี้ เข้าสู่ระบบเพื่อเพิ่มแท็ก
ประเภททรัพยากร ตำแหน่งปัจจุบัน กลุ่มข้อมูล ตำแหน่งชั้นหนังสือ เลขเรียกหนังสือ สถานะ วันกำหนดส่ง บาร์โค้ด การจองรายการ
Book Book Professor Sangvian Indaravijaya Library
General Books General Stacks HD9995.H423U5 C377 2019a (เรียกดูชั้นหนังสือ) พร้อมให้บริการ
31379015541148
Book Book Puey Ungphakorn Library, Rangsit Campus
General Books General Stacks HD9995.H423U5 C377 2019a (เรียกดูชั้นหนังสือ) Show map พร้อมให้บริการ
31379015829683
รายการจองทั้งหมด: 0

Reprint. Originally published: 2018.

Includes bibliographical references (p. [305]-324) and index.

A purposeful life -- The gluebot -- Apple envy -- Goodbye East Paly -- The childhood neighbor -- Sunny -- Dr. J -- The miniLab -- The wellness play -- "Who is LTC Shoemaker?" -- Lighting a Fuisz -- Ian Gibbons -- Chiat\Day -- Going live -- Unicorn -- The grandson -- Fame -- The Hippocratic Oath -- The tip -- The ambush -- Trade secrets -- La Mattanza -- Damage control -- The empress has no clothes -- Epilogue -- Afterword.

The full inside story of the breathtaking rise and shocking collapse of Theranos--the Enron of Silicon Valley--by the prize-winning journalist who first broke the story and pursued it to the end in the face of pressure and threats from the CEO and her lawyers. In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in an early fundraising round that valued the company at $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: the technology didn't work. For years, Holmes had been misleading investors, FDA officials, and her own employees. When Carreyrou, working at the Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both Carreyrou and the Journal were threatened with lawsuits. Undaunted, the newspaper ran the first of dozens of Theranos articles in late 2015. By early 2017, the company's value was zero and Holmes faced potential legal action from the government and her investors. Here is the riveting story of the biggest corporate fraud since Enron, a disturbing cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley.

There are no comments on this title.

เพื่อโพสต์ความคิดเห็น

คลิกที่รูปภาพเพื่อดูในตัวแสดงภาพ

ห้องสมุด:

Thammasat University Library, 2 Prachan Road, Phranakorn, Bangkok 10200

Puey Ungphakorn Library (Rangsit Campus), Circulation Desk 662 564-4444 ext. 1305

Pridi Banomyong Library, Circulation Desk 662 613-3544